MMA Embolization for Refractory Chronic Migraine

Launched by CERENOVUS, PART OF DEPUY SYNTHES PRODUCTS, INC. · Dec 11, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for people who suffer from chronic migraines that do not respond to standard treatments. Researchers want to see if a special liquid, called TRUFILL n-BCA, can be safely used to block certain blood vessels in the brain (the middle meningeal arteries) to help reduce migraine symptoms. The goal is to find out if this approach can improve the quality of life for patients who have been living with these challenging headaches.

To participate in this study, candidates need to be between 18 and 65 years old and must have a diagnosis of chronic migraines that started before they turned 50. They should also have experienced migraines that haven't improved with usual treatments. However, some people won’t be eligible, such as those with certain types of headaches, women who are pregnant or breastfeeding, or anyone currently using specific medications. If someone qualifies, they can expect to receive this new treatment and participate in follow-up evaluations to see how well it works for them. This study is not yet recruiting participants, so there will be more information available in the future.

Gender

ALL

Eligibility criteria

• Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria:
• • 1. Patient is between 18 and 65 years of age (inclusive) at the time of consent.
• • 2. Age of onset of Chronic Migraine ≤ 64 years.
• • 3. Age of onset of migraine diagnosis \< 50 years.
• • 4. Patient has a current diagnosis of refractory migraine.
• • 5. Patient has a current diagnosis of Chronic migraine.
• Participant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply:
• • 1. Patients with a history for the last 2 years of other types of headache. 2. Patients with diagnosis of hemiplegic migraine or migrainous infarct. 5. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc.
• • 6. Women who are pregnant, lactating, or who are of childbearing age. 7. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Patients in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required.